Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: A case-control study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Piranda, Diogo N ^a,b   Festa Vasconcellos, Juliana S ^a,b   Amaral, Laura M ^a   Bergmann, Anke ^c   Vianna Jorge, Rosane ^a,b  

^a Instituto Nacional de Câncer INCA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Hospital do Câncer III INCA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

3' UNTRANSLATED REGION; ADULT; AGE; ARTICLE; BODY MASS; BRAZIL; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTRACEPTION; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROSPECTIVE STUDY; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; BREAST TUMOR; GENETIC POLYMORPHISM; GENETICS; POLYMERASE CHAIN REACTION; RISK; UPREGULATION;

BRAZIL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; UP-REGULATION;

EID: 78049465813     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-613     Document Type: Article

References (64)

1. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986, 55:69-102. 10.1146/annurev.bi.55.070186.000441, 3017195.
2. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:33157-160. 10.1074/jbc.271.52.33157, 8969167.
3. Zha S, Yegnasubramanian ZS, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Letters 2004, 205:1-20. 10.1016/j.canlet.2004.06.014, 15040392.
4. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase expression in breast cancer. Cancer Res 2002, 62:632-635.
5. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. British J of Cancer 2003, 88(4):574-578.
6. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 2005, 258:115-23. 10.1111/j.1365-2796.2005.01519.x, 16018788.
7. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004, 31:22-9. 10.1053/j.seminoncol.2004.03.042, 15179621.
8. Bundred NJ, Barnes NL. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. British J of Cancer 2005, 93(Suppl 1):S10-5.
9. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 repress gene expression. Arterioscler Thromb Vasc Biol 2002, 22:1631-1636. 10.1161/01.ATV.0000030340.80207.C5, 12377741.
10. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in Cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005, 129:565-576.
11. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3'-unstranlated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986, 83:1670-4. 10.1073/pnas.83.6.1670, 323145, 2419912.
12. Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D. Polymorphism in the 3'-unstranlanted region of TNFα mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFα mRNA. Nucleic Acid Res 2001, 29:863-71. 10.1093/nar/29.4.863, 29616, 11160917.
13. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional Control of Cyclooxygenase-2 Gene Expression. The Journal of Biological Chemistry 2000, 275(16):11750-11757. 10.1074/jbc.275.16.11750, 10766797.
14. Nabors LB, Gillespie GY, Harkins L, King PH. HuR, a stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3'-unstranlated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001, 61:2154-61.
15. Panguluri RCK, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004, 25:961-6. 10.1093/carcin/bgh100, 14754878.
16. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. British J of Cancer 2004, 91:339-43.
17. CENSO 2000. Accessed Nov 28, 2007., http://www.ibge.gov.br/home/estatistica/populacao/censo2000/
18. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003, 100:177-82. 10.1073/pnas.0126614100, 140919, 12509516.
19. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity 1995, 86:248-249.
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, [PubMed ID: 15297300].
21. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004, 25:229-35. 10.1093/carcin/bgh008, 14604894.
22. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. A genetic polymorphism in prostaglandin synthase 2 (8473, T/C) and the risk of lung cancer. Cancer Letters 2005, 226:49-54. 10.1016/j.canlet.2005.03.037, 15882925.
23. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Research 2006, 6(8):R71.
24. Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Weber B, et al. The Cyclooxygenase-2 (PTGS2) 8473T > C Polymorphismis Associated with Breast Cancer Risk. Clin Cancer Res 2006, 12(4):1392-94. 10.1158/1078-0432.CCR-05-2055, 16489098.
25. Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Research 2007, 9(1):R3. 10.1186/bcr1635, 1851394, 17214885.
26. Fernandez P, de Beer PM, van der Merwe L, Heyns CF. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 2008, 29:2347-2350. 10.1093/carcin/bgn245, 18974063.
27. Upadhyaya R, Jain M, Kumarb S, Ghoshalc UC, Mittala B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutation Research 2009, 663:52-59.
28. Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, et al. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Research 2009, 15(6):2181-91.
29. Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang W-Y, et al. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 2008, 3(29):568-572.
30. Li F, Ren GS, Li HY, Wang XY, Chen L, Li J. A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol) 2009, 4:302-5.
31. Lin YC, Huang HI, Wang LH, Tsai CC, Lung O, Dai CY, et al. Polymorphisms of COX-2 -765G > C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol 2008, 44(8):798-804. 10.1016/j.oraloncology.2007.10.006, 18234542.
32. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2007, 97(4):557-61. 10.1038/sj.bjc.6603874, 2360347, 17609663.
33. Shahedi K, Lindström S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006, 119(3):668-72. 10.1002/ijc.21864, 16506214.
34. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2007, 28(9):2062.
35. Lee TS, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci 2007, 1095:134-42. 10.1196/annals.1397.017, 17404026.
36. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1126-31. 10.1158/1055-9965.EPI-06-0042, 16775170.
37. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006, 119(2):297-303. 10.1002/ijc.21858, 16482563.
38. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, Li L. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 2009, 15(18):2240-4. 10.3748/wjg.15.2240, 2682239, 19437564.
39. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al. PTGS2 and IL6 Genetic Variation and Risk of Breast and Prostate Cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2009, 31(3):455-61. 10.1093/carcin/bgp307, 19965896.
40. Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, Ambinder RF, et al. Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2009, 18(3):976-86. 10.1158/1055-9965.EPI-08-1130, 2720066, 19223558.
41. Hou L, Grillo P, Zhu ZZ, Lissowska J, Yeager M, Zatonski W, et al. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res 2007, 27(6C):4243-7.
42. Moorman PG, Sesay J, Nwosu V, Kane JG, de Cotret AR, Worley K, Millikan R. Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2005, 14(12):3013-4. 10.1158/1055-9965.EPI-05-0291, 16365029.
43. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, et al. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006, 130(7):1975-84. 10.1053/j.gastro.2006.03.021, 16762620.
44. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007, 28(6):1197-201. 10.1093/carcin/bgl242, 17151091.
45. Ali IU, Luke BT, Dean M, Greenwald P. Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 2005, 93(8):953-9. 10.1038/sj.bjc.6602806, 1369968,1369968, 16205694.
46. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 2006, 27(6):1251-6. 10.1093/carcin/bgi314, 16361272.
47. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial Asthma. J Allergy Clin Immunol 2004, 114(2):248-253. 10.1016/j.jaci.2004.05.030, 15316498.
48. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional Characterization of Cyclooxygenase-2 Polymorphisms. The Journal of Pharmacology and Experimental Therapeutics 2001, 299(2):468-76.
49. Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 2009, 136(5):1659-68. 10.1053/j.gastro.2009.01.071, 19422084.
50. SeattleSNP. Seattle, WA: NHLBI Program for Genomic Applications, (accessed every month between Jan - Oct/2008)., http://pga.gs.washington.edu
51. Gallicchio L, Mcsorley MA, Newschaffer CJ, Huang HY, Hoffman SC, Helzlsouer KJ. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006, 106(7). 10.1002/cncr.21763, 16502408.
52. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs. Cancer Epidemiol biomarkers Prev 2005, 14(3).
53. Vogel U, Christensen J, Walin H, Friis S, Nexø BA, Tjønneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutation Research 2007, 617:138-146.
54. Lira MG, Mazzola S, Tessari SG, Malerba G, Ortombina M, Nald L, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 2007, 157(1):49-57. 10.1111/j.1365-2133.2007.07921.x, 17578436.
55. Hakansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O, et al. Cyclooxygenase-2 polymorphisms in parkinson's disease. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 2007, 144B:367-369.
56. Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RYL. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. Journal of Thrombosis and Haemostasis 2006, 4:1718-1722. 10.1111/j.1538-7836.2006.02054.x, 16879213.
57. Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the atherosclerosis risk in communities study shun. Atherosclerosis 2008, 196:926-930. 10.1016/j.atherosclerosis.2007.02.010, 17350020.
58. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, et al. The cyclooxygenase 2 -765C promoter allele is a protective factor for Alzheimer's disease. Neuroscience Letters 2005,
59. Salzano FM, Freire-Maia N. Problems in human biology -- a study of Brazilian populations. 1970, 54-8. Detroit: Wayne State University Press.
60. Dornelles CL, Callegari-Jacques SM, Robinson WM, Weimer TA, Franco MHLP, Hickmann AC, et al. Genetics, surnames, grandparents' nationalities and ethnic admixture in Southern Brazil: do the patterns of variation coincide?. Genet Mol Biol 1999, 22:151-61.
61. Alves-Silva J, Santos MS, Guimarães PE, Ferreira AC, Bandelt HJ, Pena SD, et al. The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 2000, 67:444-61. 10.1086/303004, 1287189, 10873790.
62. Sans M. Admixture studies in Latin America: from the 20th to the 21st century. Hum Biol 2000, 72:155-77.
63. Krieger H, Morton NE, Mi MP, Azevedo E, Freire-Maia A, Yasuda N. Racial admixture in north-eastern Brazil. Ann Hum Genet 1965, 29:113-25. 10.1111/j.1469-1809.1965.tb00507.x, 5863835.
64. Zhu W, Wei BB, Shan X, Liu P. -765G > C and 8473T > C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 2009,